Literature DB >> 15196940

Receptor binding specificities of Herstatin and its intron 8-encoded domain.

Lara S Shamieh1, Adam J Evans, Michael C Denton, Gail M Clinton.   

Abstract

Retention of intron 8 in alternative HER-2 mRNA generates an inhibitory secreted ligand, Herstatin, with a novel receptor-binding domain (RBD) encoded by the intron. This study examines binding interactions with several receptors and investigates sequence variations in intron 8. The RBD, expressed as a peptide, binds at nM concentrations to HER-2, the EGFR, DeltaEGFR, HER-4 and to the IGF-1 receptor, but not to HER-3 nor to the FGF-3 receptor, whereas a rare mutation in the RBD (Arg to Ile) eliminates receptor binding. The full-length Herstatin binds with 3-4-fold higher affinity than its RBD, but with approximately 10-fold lower affinity to the IGF-IR. Sequence conservation in rhesus monkey but not in rat suggests that intron 8 recently diverged as a receptor-binding module critical for the function of Herstatin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196940     DOI: 10.1016/j.febslet.2004.05.027

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

Review 1.  ErbB receptor negative regulatory mechanisms: implications in cancer.

Authors:  Colleen Sweeney; Jamie K Miller; David L Shattuck; Kermit L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

2.  Intron-Encoded Domain of Herstatin, An Autoinhibitor of Human Epidermal Growth Factor Receptors, Is Intrinsically Disordered.

Authors:  Daisuke Tashiro; Shunji Suetaka; Nao Sato; Koji Ooka; Tomoko Kunihara; Hisashi Kudo; Junichi Inatomi; Yuuki Hayashi; Munehito Arai
Journal:  Front Mol Biosci       Date:  2022-05-02

3.  A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas.

Authors:  Triantafyllia Koletsa; Ioannis Kostopoulos; Elpida Charalambous; Barbara Christoforidou; Eleni Nenopoulou; Vassiliki Kotoula
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.